Therapeutic approaches using multipotent mesenchymal stromal cells (MSCs) are advancing in regenerative medicine, transplantation, and autoimmune diseases. The mechanisms behind MSC immune modulation are still poorly understood and the prediction of the immune modulatory potential of single MSC preparations remains a major challenge for possible clinical applications. Here, we highlight galectin-9 (Gal-9) as a novel, important immune modulator expressed by MSCs, which is strongly upregulated upon activation of the cells by interferon-γ (IFN-γ). Further, we demonstrate that Gal-9 is a major mediator of the anti-proliferative and functional effects of MSCs not only on T cells but also on B cells. Here, Gal-9 and activated MSCs contribute to the suppression of antigen triggered immunoglobulin release. Moreover, we determined that Gal-9 expression could serve as a marker to predict a higher or lower immune modulatory potential of single cell preparations and therefore to distinguish the therapeutic potency of MSCs derived from different donors. Also in vivo co-administration of MSCs or murine Gal-9 resulted in significantly reduced IgG titers in mice immunized with human coagulation factor VIII (FVIII). In conclusion, Gal-9 acts as an immune modulator interfering with multiple cell types including B cells and Gal-9 may serve as a predictive indicator for clinical MSC therapy.
Get full access to this article
View all access options for this article.
References
1.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI and FiskNM. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98:2396–2402.
2.
in ’t AnkerPS, NoortWA, ScherjonSA, Kleijburg-van der KeurC, KruisselbrinkAB, van BezooijenRL, BeekhuizenW, WillemzeR, KanhaiHH and FibbeWE. (2003). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica, 88:845–852.
CiapettiG, GranchiD and BaldiniN. (2012). The combined use of mesenchymal stromal cells and scaffolds for bone repair. Curr Pharm Des, 18:1796–1820.
5.
LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun-PrietoL, DelafontaineP and ProckopDJ. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54–63.
6.
BassiEJ, AitaCA and CamaraNO. (2011). Immune regulatory properties of multipotent mesenchymal stromal cells: where do we stand?. World J Stem Cells, 3:1–8.
7.
YanezR, LamanaML, Garcia-CastroJ, ColmeneroI, RamirezM and BuerenJA. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24:2582–2591.
8.
ZhangJ, LiY, ChenJ, CuiY, LuM, EliasSB, MitchellJB, HammillL, VanguriP and ChoppM. (2005). Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol, 195:16–26.
9.
GriffinMD, RitterT and MahonBP. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther, 21:1641–1655.
10.
Le BlancK, RasmussonI, SundbergB, GotherstromC, HassanM, UzunelM and RingdenO. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363:1439–1441.
11.
WangS, QuX and ZhaoRC. (2012). Clinical applications of mesenchymal stem cells. J Hematol Oncol, 5:19
12.
NautaAJ and FibbeWE. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110:3499–3506.
13.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS and GianniAM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
14.
TseWT, PendletonJD, BeyerWM, EgalkaMC and GuinanEC. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75:389–397.
15.
MeiselR, ZibertA, LaryeaM, GobelU, DaubenerW and DillooD. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103:4619–4621.
16.
RyanJM, BarryF, MurphyJM and MahonBP. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149:353–363.
17.
GiesekeF, BohringerJ, BussolariR, DominiciM, HandgretingerR and MullerI. (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood, 116:3770–3779.
18.
SioudM, MobergslienA, BoudabousA and FloisandY. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol, 71:267–274.
19.
ThijssenVL, PoirierF, BaumLG and GriffioenAW. (2007). Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood, 110:2819–2827.
20.
GrigorianA, TorossianS and DemetriouM. (2009). T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev, 230:232–246.
21.
WadaJ and KanwarYS. (1997). Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem, 272:6078–6086.
22.
DardalhonV, AndersonAC, KarmanJ, ApetohL, ChandwaskarR, LeeDH, CornejoM, NishiN, YamauchiA, et al. (2010). Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 185:1383–1392.
23.
BiS, HongPW, LeeB and BaumLG. (2011). Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A, 108:10650–10655.
24.
AsakuraH, KashioY, NakamuraK, SekiM, DaiS, ShiratoY, AbedinMJ, YoshidaN, NishiN, et al. (2002). Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol, 169:5912–5918.
25.
ImaizumiT, KumagaiM, SasakiN, KurotakiH, MoriF, SekiM, NishiN, FujimotoK, TanjiK, et al. (2002). Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol, 72:486–491.
26.
SakaiK, KawataE, AshiharaE, NakagawaY, YamauchiA, YaoH, NagaoR, TanakaR, YokotaA, et al. (2011). Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol, 41:67–75.
27.
LeeSB, SchrammeA, DobersteinK, DummerR, Abdel-BakkyMS, KellerS, AltevogtP, OhST, ReichrathJ, et al. (2010). ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol, 130:763–773.
28.
MilanovP, IvanciuL, AbrissD, Quade-LyssyP, MiesbachW, AlesciS, TonnT, GrezM, SeifriedE and SchuttrumpfJ. (2012). Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood, 119:602–611.
29.
CiuculescuF, GiesenM, DeakE, LangV, SeifriedE and HenschlerR. (2011). Variability in chemokine-induced adhesion of human mesenchymal stromal cells. Cytotherapy, 13:1172–1179.
30.
GiesekeF, KruchenA, TzaribachevN, BentzienF, DominiciM and MullerI. (2013). Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol, 43:2741–2749.
31.
BiS, EarlLA, JacobsL and BaumLG. (2008). Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem, 283:12248–12258.
32.
FibbeWE, NautaAJ and RoelofsH. (2007). Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci, 1106:272–278.
33.
ChenK, WangD, DuWT, HanZB, RenH, ChiY, YangSG, ZhuD, BayardF and HanZC. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol, 135:448–458.
34.
De MiguelMP, Fuentes-JulianS, Blazquez-MartinezA, PascualCY, AllerMA, AriasJ and Arnalich-MontielF. (2012). Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med, 12:574–591.
35.
GhannamS, BouffiC, DjouadF, JorgensenC and NoelD. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther, 1:2
36.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
37.
AlamS, LiH, MargaritiA, MartinD, ZampetakiA, HabiO, CockerillG, HuY, XuQ and ZengL. (2011). Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J Biol Chem, 286:44211–44217.
38.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB and BartholomewA. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
39.
KronsteinerB, WolbankS, PeterbauerA, HacklC, RedlH, van GriensvenM and GabrielC. (2011). Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev, 20:2115–2126.
40.
GiesekeF, SchuttB, ViebahnS, KoscielniakE, FriedrichW, HandgretingerR and MullerI. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood, 110:2197–2200.
OhtsuboK, TakamatsuS, MinowaMT, YoshidaA, TakeuchiM and MarthJD. (2005). Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell, 123:1307–1321.
43.
KashioY, NakamuraK, AbedinMJ, SekiM, NishiN, YoshidaN, NakamuraT and HirashimaM. (2003). Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol, 170:3631–3636.
44.
ZhuC, AndersonAC, SchubartA, XiongH, ImitolaJ, KhourySJ, ZhengXX, StromTB and KuchrooVK. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 6:1245–1252.
45.
PatelSA, MeyerJR, GrecoSJ, CorcoranKE, BryanM and RameshwarP. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol, 184:5885–5894.
46.
LiuX, QuX, ChenY, LiaoL, ChengK, ShaoC, ZenkeM, KeatingA and ZhaoRC. (2012). Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol, 189:1182–1192.
47.
LiY, FengJ, GengS, WeiH, ChenG, LiX, WangL, WangR, PengH, HanG and ShenB. (2011). The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol Immunol, 48:670–677.
48.
KatohS, IshiiN, NobumotoA, TakeshitaK, DaiSY, ShinonagaR, NikiT, NishiN, TominagaA, YamauchiA and HirashimaM. (2007). Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med, 176:27–35.
49.
CampRL, KrausTA, BirkelandML and PureE. (1991). High levels of CD44 expression distinguish virgin from antigen-primed B cells. J Exp Med, 173:763–766.
RasmussonI, Le BlancK, SundbergB and RingdenO. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol, 65:336–343.
RenG, SuJ, ZhangL, ZhaoX, LingW, L'HuillieA, ZhangJ, LuY, RobertsAI, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27:1954–1962.
54.
ReipertBM, AllacherP, HauslC, PordesAG, AhmadRU, LangI, IlasJ, WindygaJ, KlukowskaA, MuchitschEM and SchwarzHP. (2010). Modulation of factor VIII-specific memory B cells. Haemophilia, 16:25–34.
55.
RafeiM, HsiehJ, FortierS, LiM, YuanS, BirmanE, FornerK, BoivinMN, DoodyK, et al. (2008). Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood, 112:4991–4998.
56.
MoritokiM, KadowakiT, NikiT, NakanoD, SomaG, MoriH, KobaraH, MasakiT, KohnoM and HirashimaM. (2013). Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS One, 8:e60807
57.
LvK, ZhangY, ZhangM, ZhongM and SuoQ. (2012). Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One, 7:e48379
58.
FukushimaA, SumiT, FukudaK, KumagaiN, NishidaT, OkumuraK, AkibaH, YagitaH and UenoH. (2008). Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. Int Arch Allergy Immunol, 146:36–43.
59.
de KivitS, SaelandE, KraneveldAD, van de KantHJ, SchoutenB, van EschBC, KnolJ, SprikkelmanAB, van der AaLB, et al. (2012). Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy, 67:343–352.
60.
AbdiR, FiorinaP, AdraCN, AtkinsonM and SayeghMH. (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 57:1759–1767.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
